PANTHER-IPF: Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People with Idiopathic Pulmonary Fibrosis



Trial Objective

To assess the safety and efficacy of N-acetylcysteine (NAC) and the combination of prednisone, azathioprine, and NAC in subjects with newly diagnosed idiopathic pulmonary fibrosis

Patient Groups:
390 patients will enroll in the study from 22 centers in the United States.

  • 130 patients will receive will receive a placebo.
  • 130 patients will receive will receive a NAC only.
  • 130 patients will receive will receive a combination therapy of prednisone, azathioprine, and NAC

Visits:

  • Approximately 8 study visits over 13 months
  • Screening visit to determine eligibility
  • Study visits 4 weeks and every 15 weeks after enrollment visit
  • Post treatment safety follow-up, up to 28 days after treatment

Enrollment

Active Clinical Trials Closed to Recruitment

How to Participate

For more information, contact the Clinical and Research Coordinator, Carol Bair by phone at 303.398.1912 or complete the form below.

Who Can Participate

  • Male or female patients between 35 and 80 years of age
  • Diagnosis of IPF in the 48 months before study entry

Trial Location

Main Campus, Denver, CO

Compensation

Not Provided